<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349348</url>
  </required_header>
  <id_info>
    <org_study_id>156-08-805-01</org_study_id>
    <nct_id>NCT01349348</nct_id>
  </id_info>
  <brief_title>Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites</brief_title>
  <official_title>A Randomized, Double-blinded, Multicenter, Placebo Controlled, Parallel Designed Study, to Evaluate the Efficacy and Safety of Tolvaptan Tablet in Treatment of Patients With Cirrhosis Ascites, Using Diuretics as Initial Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Tolvaptan 7.5mg and 15mg in treatment of patients with&#xD;
      cirrhosis ascites who fail to response adequately to treatment with common diuretics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For symptoms of fluid retention due to liver diseases (ascites and/or lower extremity edema,&#xD;
      i.e. hepatic edema), treatment generally starts with bed rest and a low-salt diet.&#xD;
      Aldosterone antagonists and loop diuretics are commonly used diuretics in the treatment of&#xD;
      fluid retention due to liver diseases. In aldosterone antagonists' therapy, nevertheless,&#xD;
      hyperkalemia is frequently reported, slow onset of action and dose escalation needed also&#xD;
      impair its effect. If aldosterone antagonists' therapy is ineffective, loop diuretics as&#xD;
      strong diuretics are usually added up. However, Dose escalation of loop diuretics also boost&#xD;
      the occurrence of hyponatremia and hypokalemia, and combination of the two drugs provided&#xD;
      fastest onset of effectiveness with less adverse events. While, because both diuretics can&#xD;
      cause sodium lose which is difficult to prevent and treat, hyponatremia is easy to occur. The&#xD;
      combination of aldosterone antagonists and K-sparing diuretics reduces the occurrence of&#xD;
      hypokalemia but have little effect on the prevention and treatment of hyponatremia. In&#xD;
      addition, there are still some patients who are resistent to loop diuretics or intolerant of&#xD;
      an effective diuretic dosage due to adverse events.&#xD;
&#xD;
      Tolvaptan increases the excretion of electrolyte-free water (aquaretic) without changing&#xD;
      electrolytes excretion by inhibiting the water reabsorption of collecting duct in kidney. It&#xD;
      is demonstrated that Tolvaptan increased urine volume without impairing renal function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in body weight after 7 days randomized treatment (Day 8).</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight after 4 days randomized treatment (Day 5);</measure>
    <time_frame>4days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of change from baseline in body weight after 4, 7 days randomized treatment (Day 5, Day 8);</measure>
    <time_frame>4 and 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">535</enrollment>
  <condition>Ascites</condition>
  <condition>Hepatic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Tolvaptan 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet;15mg/tab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolvaptan 7.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet;7.5mg/tab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tolvaptan 0mg/tab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>tablet, 15 mg, Qd, for 7 days</description>
    <arm_group_label>Tolvaptan 15mg</arm_group_label>
    <other_name>SAMSCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>tablet, 7.5 mg, Qd, for 7 days</description>
    <arm_group_label>Tolvaptan 7.5mg</arm_group_label>
    <other_name>SAMSCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet, 7.5/15mg , Qd, 7days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Blank tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients diagnosed with liver cirrhosis clinically or pathologically;&#xD;
&#xD;
          2. Patients with ascites confirmed by Type-B ultrasound scan after receiving combination&#xD;
             therapies of oral loop diuretics and aldosterone antagonists for at least 4 days with&#xD;
             the fixed usage and dosage&#xD;
&#xD;
          3. Inpatients or patients who can be hospitalized for this study from Day -3 (Screening)&#xD;
             to Day 8 (the day for efficacy evaluation);&#xD;
&#xD;
          4. Patients with body weight change within ±1.0 kg in the 2 days prior to initiation of&#xD;
             treatment (Day -2 and Day -1)&#xD;
&#xD;
          5. Age: 18 to 75 years, inclusive(at the time informed consent is obtained);&#xD;
&#xD;
          6. Genders: men or women;&#xD;
&#xD;
          7. Patients who have signed informed consent form.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients with any of the following diseases, complications or symptoms:&#xD;
&#xD;
               -  Hepatic encephalopathy (hepatic coma of grade II or higher1）);&#xD;
&#xD;
               -  Malignant ascites (patients have tumor cells detected in ascites if malignant&#xD;
                  ascites be highly suspected);&#xD;
&#xD;
               -  Uncontrolled spontaneous bacterial peritonitis;&#xD;
&#xD;
               -  Patients who are likely to experience alimentary tract hemorrhage during the&#xD;
                  study;&#xD;
&#xD;
               -  Heart failure (NYHA2） grade III or IV);&#xD;
&#xD;
               -  Anuresis (daily urine volume is less than 100mL);&#xD;
&#xD;
               -  Dysuria due to urinary tract stricture, urinary calculus, tumor in the urinary&#xD;
                  tract or other cause.&#xD;
&#xD;
          2. Patients with history of :&#xD;
&#xD;
               -  Alimentary tract hemorrhage within 10 days prior to screening;&#xD;
&#xD;
               -  Cerebral accident suffered within 30 days prior to screening;&#xD;
&#xD;
               -  Past history of hypersensitivity or idiosyncratic reaction to benzazepine&#xD;
                  derivatives (Benazepril).&#xD;
&#xD;
          3. Patients with systolic pressure below 90mmHg at screening;&#xD;
&#xD;
          4. Patients with any of the following abnormal laboratory parameters at screening:&#xD;
&#xD;
               -  Serum creatinine &gt;1.5x upper limit of normal range;&#xD;
&#xD;
               -  Serum Na+&gt;145mmol/L (or higher than upper limit of normal range);&#xD;
&#xD;
               -  Serum K+&gt;5.5mmol/L;&#xD;
&#xD;
          5. Patients with Child-pugh score3）&gt;12;&#xD;
&#xD;
          6. Patients who are unable to take medicine orally;&#xD;
&#xD;
          7. Female patients who are pregnant, lactating, or who are at child-bearing age without&#xD;
             using acceptable contraceptive means;&#xD;
&#xD;
          8. Patients who received blood products including albumin within 4 days prior to the&#xD;
             initiation of treatment&#xD;
&#xD;
          9. Patients who participated in any clinical trial other than tolvaptan within one month&#xD;
             prior to screening;&#xD;
&#xD;
         10. Patients who participated in Tolvaptan trials and took Tolvaptan previously;&#xD;
&#xD;
         11. Patients otherwise judged by the investigator, to be inappropriate for inclusion in&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minde Zeng</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <last_update_submitted>October 10, 2012</last_update_submitted>
  <last_update_submitted_qc>October 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolvaptan treatment to ascites and hepatic cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

